INTRODUCTION
============

Oocyte meiotic resumption leads to the completion of the first meiotic asymmetric division, after which oocytes enter meiosis II before arresting at metaphase II (MII) until fertilization. A disruption in any one of these cellular events usually results in aged oocytes of poor quality, which may affect fertilization outcomes and result in mammalian infertility. Despite substantial progress in assisted reproduction technologies (ART), many failures are the result of oocyte aging ([@b27-ajas-27-5-635-4]). Chromosomal abnormalities, spindle defects, mitochondrial dysfunction, and a decrease in the levels of maturation-promoting factor (MPF) and mitogen-activated protein kinase (MAPK) are directly implicated in age-related declines in fertility and embryonic development ([@b6-ajas-27-5-635-4]; [@b41-ajas-27-5-635-4]; [@b19-ajas-27-5-635-4]; [@b31-ajas-27-5-635-4]; [@b2-ajas-27-5-635-4]). [@b21-ajas-27-5-635-4] reported that the mitogen-activated protein kinase kinase (MEK)/MAPK pathway regulates microtubule and centrosome assembly. In the absence of centrosome and microtubule stability, oocytes cannot be fertilized or, alternatively, fertilized oocytes display aneuploidy and developmental abnormalities.

While there is little knowledge on the mechanism of oocyte aging, there is a general consensus that it associates with an increase in intracellular oxidative damage ([@b32-ajas-27-5-635-4]). An increase in reactive oxygen species (ROS) production over time may lead to a decrease in the intracellular adenosine triphosphate (ATP) concentration and the glutathione/glutathione disulfide ratio as well as to a concomitant increase in cytosolic calcium ions, which are all detrimental to oocyte health and embryo development ([@b36-ajas-27-5-635-4]). [@b11-ajas-27-5-635-4] proposed a theory of aging which states that damage caused by ROS leads to cell senescence. Since ROS are produced mainly as by-products of mitochondrial respiration, mitochondria play a fundamental role in aging and represent putative targets of anti-aging strategies ([@b26-ajas-27-5-635-4]).

Recently, it has been proposed that the main driver of aging is target of rapamycin (TOR) signaling rather than ROS ([@b4-ajas-27-5-635-4]). Inhibition of TOR, either pharmacologically with rapamycin or genetically, extends the life span of yeast, *C. elegans* ([@b17-ajas-27-5-635-4]), *D. melanogaster* ([@b3-ajas-27-5-635-4]), and mice ([@b13-ajas-27-5-635-4]). Furthermore, TOR is a negative regulator of autophagy in organisms from yeast to man because knockout or knockdown of *ATG* genes can abolish the lifespan-extending effects of rapamycin in all species investigated ([@b3-ajas-27-5-635-4]). However, the mechanism behind the positive effects of rapamycin on lifespan remains largely unexplored.

Rapamycin, a bacterial macrolide with antifungal and immunosuppressant activities ([@b7-ajas-27-5-635-4]), can form a complex with FK506 binding protein 12 and then bind mTOR, selectively inhibiting its kinase activity and function ([@b9-ajas-27-5-635-4]). Intensive studies have focused on the crucial roles of mTOR in controlling cell proliferation, growth, and survival. Rapamycin also inhibits F-actin reorganization and cell motility, at least in part, by downregulating the level and activity of RhoA through mTORC1-mediated S6K1- and 4E-BP1-signaling pathways. In particular, the inhibition of mTOR by rapamycin affected the formation of the actin cap and the cortical granules-free domain (CGFD), and disrupted peripheral spindle migration and asymmetric division during oocyte meiotic maturation ([@b22-ajas-27-5-635-4]). However, it is still not known whether rapamycin treatment affects cytoskeleton dynamics in developing porcine early embryos.

The objective of this *in vitro* study was to investigate the effects of appropriate concentrations of rapamycin on nuclear and cytoplasmic maturation and the developmental capacity of aged porcine oocytes, and to better understand the link between the production of mitochondrial ROS and mTOR signaling. We demonstrate that rapamycin can stabilize microtubules and centrosomes, possibly by maintaining a balance between molecules involved in the maturation of metaphase II (MII) oocytes. These findings may be applicable to IVF procedures, and they may help to overcome oocyte aging.

MATERIALS AND METHODS
=====================

Chemicals and reagents
----------------------

All chemicals and reagents were purchased from Sigma (St. Louis, MO, USA) unless otherwise stated.

Antibodies
----------

Rabbit polyclonal anti-mTOR and mouse monoclonal anti-α-tubulin--FITC antibodies were purchased from Abcam (Cambridge, UK) and Sigma, respectively. Rabbit polyclonal anti-p44/42 MAP Kandanti-phospho-p44/42 MAPK antibodies and anti-rabbit IgG--HRP were purchased from Cell Signaling Technology (Danvers, MA, USA). An Alexa Fluor488 goat anti-rabbit secondary antibody was purchased from Invitrogen (Carlsbad, CA, USA).

*In vitro* maturation and aging of porcine oocytes
--------------------------------------------------

Prepubertal porcine ovaries were collected from a local slaughterhouse and transported to the laboratory at 25°C in Dulbecco's phosphate-buffered saline (DPBS) supplemented with 75 μg/L penicillin G and 50 μg/L streptomycin sulfate. Cumulus-oocyte complexes (COCs) were aspirated from follicles 2 to 8 mm in diameter with an 18-gauge needle and a disposable 10 mL syringe. The COCs were washed three times in tissue culture medium (TCM)-199-HEPES containing 0.1% (w/v) bovine serum albumin (BSA) (TCM-HEPES-BSA). Groups of 50 COCs were matured in 500 μL TCM-199 (Gibco, Grand Island, NY, USA) containing Earle's salts, 0.57 mM cysteine, 10 ng/mL epidermal growth factor (EGF), 0.5 μ/mL follicle stimulating hormone (FSH), 0.5 μg/mL luteinizing hormone (LH), and 10% (v/v) porcine follicular fluid under mineral oil for 44 h at 38.8°C. Oocyte aging was initiated by culturing oocytes with cumulus cells for an additional 24 or 48 h in TCM-199.

Rapamycin treatment
-------------------

Mature oocytes were covered with mineral oil and cultured in wells of a four-well multidish containing 500 μL TCM-199 at 38.8°C in a humidified atmosphere of 5% CO~2~ and 95% air. After maturation, MII stage oocytes were transferred into TCM-199 containing 0, 0.1, 1, 10, and 50 μM rapamycin (Sigma) and cultured for 24 or 48 h (68 or 92 h for *in vitro* maturation \[IVM\]) as described above. After treatment, oocytes were collected and aging was assessed.

Parthenogenetic activation and embryo culture
---------------------------------------------

Following maturation, cumulus cells were removed by pipetting in the presence of 1 mg/mL hyaluronidase for 2 to 3 min. Oocytes were parthenogenetically activated with 5 μM Ca^2+^ ionomycin (Sigma) for 5 min. After 3 h of culture in porcine zygote medium-5 (PZM-5) containing 7.5 μg/mL cytochalasin B (Sigma), embryos were washed three times in PZM-5 containing 0.4% (w/v) BSA and cultured in the same medium for 7 days at 38.8°C in a humidified atmosphere of 5% CO~2~ and 95% air. The oocytes and embryos were washed in DPBS, and depending on the experiment, either fixed in 3.7% (w/v) paraformaldehyde for 20 min and stored at 4°C, or snap-frozen in liquid nitrogen and stored at −70°C.

Measurement of intracellular reactive oxygen species
----------------------------------------------------

Intracellular ROS activity in oocytes and embryos was measured by a 2,7-dichlorofluorescene assay, as previously described ([@b10-ajas-27-5-635-4]). In brief, oocytes and embryos were incubated with 100 μM 2,7-dichlorodihydrofluorescein diacetate (DCHFDA) for 20 min at 38.8°C, washed three times in PZM-5 to remove excess dye, and immediately analyzed by epifluorescence microscopy (Olympus, Tokyo, Japan) using excitation and emission wavelengths of 450 to 490 nm and 515 to 565 nm, respectively. Gray scale images were acquired with a digital camera (Nikon, Tokyo, Japan) attached to the microscope, and mean gray values were measured with Image J software (NIH, Bethesda, MD, USA). Background fluorescent values were subtracted from the final values before statistical analysis. The experiment was repeated four independent times with each experiment consisting of 25 to 30 oocytes.

Confocal microscopy
-------------------

Confocal microscopy was performed as previously described ([@b22-ajas-27-5-635-4]). In brief, oocytes were fixed with 3.7% (w/v) paraformaldehyde in phosphate buffered saline (PBS) overnight at 4°C and then transferred to membrane permeabilization solution (0.5% (v/v) Triton X100 in PBS) for 30 min. After 1 h in blocking buffer (1% (w/v) BSA in PBS), oocytes were incubated with an anti-mTOR (1:100) or anti-α-tubulin-FITC (1:200) antibody in blocking buffer overnight at 4°C. After three washes in PBS containing 0.5% (v/v) Tween 20 and 0.5% (v/v) Triton X-100, the oocytes were labeled with Alexa Fluor 488 goat anti-rabbit IgG (1:100) for 1 h at room temperature to visualize mTOR. To visualize α-tubulin--FITC, oocytes were washed three times in PBS containing 0.5% (v/v) Tween 20 and 0.5% (v/v) Triton X-100 for 2 min each. A 30 min incubation of porcine blastocysts with MitoTracker Green FM (Molecular Probes, Eugene, OR, USA) stained mitochondria. To detect fragmented DNA, embryos were incubated with fluorescein-conjugated dUTP and terminal deoxynucleotidyl transferase (*in situ* Cell Death Detection Kit, Roche, Mannheim, Germany) in the dark for 1 h at 37°C. The total number of mitotic and apoptotic cells was scored. The percentage of apoptotic cells per embryo was expressed as follows: apoptotic index = (no. of apoptotic nuclei/total no. of nuclei)×100. Nuclei were stained with Hoechst 33342 (1 μg/mL) for 30 min, and embryos were washed in PBS/polyvinyl alcohol (PVA). Oocytes were mounted onto glass slides and examined under a model FV500 confocal laser-scanning microscope (Olympus). At least 20 oocytes were examined from each group.

Real-time quantitative PCR
--------------------------

mRNA was isolated from groups of 20 *in vitro*-cultured embryos using the Dynabeads mRNA Direct Kit (DynalAsa, Oslo, Norway). First-strand cDNA synthesis was achieved by the reverse transcription of mRNA using an oligo(dT)~12--18~ primer and SuperScript III reverse transcriptase (Invitrogen, Grand Island, NY, USA). Real-time PCR was performed in a DNA Engine OPTICON 2 system (MJ Research, Waltham, MA, USA) in a final reaction volume of 20 μL that contained SYBR Green and a double-stranded DNA-binding fluorophore (qPCR Kit; FINNZYMES, Espoo, Finland). The primers used for PCR are listed in [Table 1](#t1-ajas-27-5-635-4){ref-type="table"}. The PCR conditions were as follows: 10 min at 94°C, followed by 39 cycles of 30 s at 94°C, 30 s at 60°C and 55 s at 72°C, and a final extension of 5 min at 72°C. Relative gene expression was analyzed by the 2-ΔΔCt method ([@b23-ajas-27-5-635-4]) after normalization against the *GAPDH* mRNA level.

Western blot analysis
---------------------

The protocol was basically the same as the one described previously ([@b22-ajas-27-5-635-4]). In brief, oocytes (40 oocytes per sample) were solubilized in 20 mL 1× sodium dodecyl sulfate (SDS) sample buffer (62.5 mM Tris-HCl pH 6.8, containing 2% (w/v) SDS, 10% (v/v) glycerol, 50 mM DTT, and 0.01% (w/v) bromophenol blue or phenol red) and heated for 5 min at 95°C. For western blotting, proteins were resolved on a 5% to 12% Tris-SDS-PAGE gel for 1.5 h at 80 to 100 V. Samples were then transferred onto a nitrocellulose membrane (Amersham, Hybond-ECL, Buckinghamshire, UK) at 300 mA for 2 h in transfer buffer (25 mM Tris, pH 8.5, containing 200 mM glycine and 20% (v/v) methanol). After blocking with 5% (w/v) nonfat milk in PBS for 1 h, the membrane was incubated for at least 2 h with an anti-p44/42 MAPK or anti-phospho-p44/42 MAPK antibody diluted 1:500 in blocking solution (1× TBS, pH 7.5, containing 0.1% (v/v) Tween-20 and 5% (w/v) nonfat milk). Thereafter, the membrane was washed three times in Tris-Buffered Saline and Tween 20 (TBST, 20 mM Tris-HCl, pH 7.5, containing 250 mM NaCl and 0.1% (v/v) Tween-20) and incubated for 1 h with anti-rabbit IgG-HRP diluted 1:2,000 in blocking solution. After three washes with TBST, antibody binding was visualized with chemiluminescence luminal reagent (Invitrogen).

Statistical analysis
--------------------

The general linear model (GLM) procedure embedded in the Statistical Analysis System (SAS User's Guide, 1985, Statistical Analysis System Inc., Cary, NC. USA) was used to analyze data from all experiments. Significant differences were determined by Tukey's multiple range test. P-values of \<0.05 were considered significant.

RESULTS
=======

Rapamycin enhances the *in vitro* development of aged porcine oocytes
---------------------------------------------------------------------

To determine the optimal concentration of rapamycin to use, 44 h IVM porcine oocytes were further cultured in IVM medium supplemented with different concentrations (0, 0.1, 1, 10, and 50 μM) of rapamycin for 24 h (total IVM time: 68 h) or 48 h (total IVM time: 96 h). As shown in [Table 2](#t2-ajas-27-5-635-4){ref-type="table"}, there were no differences in the percentage of MII oocytes among control IVM (44 h, 76.00±4.53%), untreated 24 h-aged IVM (68 h, 77.67±2.33%), and rapamycin-treated (75.00±8.74 to 77.56±8.25%) groups. However, in the 48 h-aged IVM group (44 h+wo/w rapamycin/48 h), the percentage of MII oocytes was significantly lower than those of control IVM and 24 h-aged IVM groups, except for 1 μM and 10 μM rapamycin-treated groups (p\<0.05). Porcine IVM oocytes in control, 24 h- and 48 h-aged, and rapamycin-treated groups were parthenoted. There was no difference in the frequency of cleavage into 2 to 4 cells in 10 μM rapamycin-treated 24 h-aged IVM and 48 h-aged IVM groups (44 h+10 μM rapamycin/24 h; 66.10±0.29% and 44 h+10 μM rapamycin/48 h; 68.01±6.04%) compared with the control IVM group (63.97±3.11%). However, there were significant decreases (p\<0.05) in 50 μM rapamycin-treated 48 h-aged IVM (43.97±14.15 to 52.01±4.88%) and untreated 48 h-aged IVM (92 h, 45.44±7.51%) groups compared with the control IVM group.

The frequency of development into blastocysts was calculated as the number of blastocysts on day 2 that developed from cleaved embryos. Compared with the control IVM group, only the 10 μM rapamycin-treated 24 h-aged IVM group had no difference in the frequency of development into blastocysts (42.14±4.40% and 47.52±5.68%, respectively). Furthermore, this frequency of development into blastocysts was significantly higher than those of the other groups (24 h-aged groups: 44 h+rapamycin/24 h \[14.14±3.17 to 28.54±2.49%\]; and 48 h-aged groups: 44 h+rapamycin/48 h \[4.95±2.48% to 13.50±1.26%\]) (p\<0.05).

Rapamycin treatment improves the quality of blastocysts developed from rapamycin-treated porcine oocytes
--------------------------------------------------------------------------------------------------------

The quality of blastocysts developed from 10 μM rapamycin-treated 24 h-aged IVM oocytes (44 h+10R/24 h, [Figure 1A, c](#f1-ajas-27-5-635-4){ref-type="fig"}) was better than that of blastocysts developed from the untreated 24 h-aged IVM group (68 h, [Figure 1A, b](#f1-ajas-27-5-635-4){ref-type="fig"}). Blastocyst quality was also better than the control IVM group (44 h, [Figure 1A, a](#f1-ajas-27-5-635-4){ref-type="fig"}). The total number of cells in control IVM (n = 67.25±4.18) and 10 μM rapamycin-treated 24 h-aged IVM (n = 57.75±1.52, p\<0.05) groups was significantly higher than that of the untreated 24 h-aged IVM group (n = 47.00±3.90, p\<0.01, [Figure 1B](#f1-ajas-27-5-635-4){ref-type="fig"}). When genomic DNA fragmentation (i.e., an indicator of apoptosis) was measured in individual embryos with the TUNEL assay, the index was significantly lower in the 10 μM rapamycin-treated 24 h-aged IVM group (2.53±0.66%) than those of untreated 24 h-aged IVM (4.88±0.87%, p\<0.05) and control IVM (2.10±0.60%) groups ([Figure 1C](#f1-ajas-27-5-635-4){ref-type="fig"}).

Rapamycin rescues aberrant spindle organization and chromosomal misalignment of aged porcine oocytes *in vitro*
---------------------------------------------------------------------------------------------------------------

To further investigate the effect of rapamycin on spindle organization, we treated oocytes with 10 μM rapamycin. As shown in [Figure 2A](#f2-ajas-27-5-635-4){ref-type="fig"}, there were no spindle abnormalities in 10 μM rapamycin-treated 24 h-aged IVM oocytes (44 h+10R/24 h, [Figure 2A, d](#f2-ajas-27-5-635-4){ref-type="fig"}), similar to control IVM oocytes ([Figure 2A, a](#f2-ajas-27-5-635-4){ref-type="fig"}), usually the failure of chromosomes to align at the metaphase plate, compared with aged oocytes ([Figure 2A, b--c](#f2-ajas-27-5-635-4){ref-type="fig"}). There was a significant difference in the frequency of oocytes showing normal meiotic spindles among untreated 24 h-aged IVM (68 h, 28.57±6.21%), 10 μM rapamycin-treated 24 h-aged IVM (44 h+10R/24 h, 71.43±7.68%), and control IVM (44 h, 66.67±5.46%) groups (p\<0.05) ([Figure 2B](#f2-ajas-27-5-635-4){ref-type="fig"}).

Rapamycin increases molecular maturation factors in porcine oocytes *in vitro*
------------------------------------------------------------------------------

To examine the effect of rapamycin treatment on the maturation of aged oocytes at the molecular level, we investigated MAPK activity and maternal gene expression ([Figure 3](#f3-ajas-27-5-635-4){ref-type="fig"}). Active phosphorylated p44/42 MAPK (phospho-p44/42 MAPK) appeared as a doublet in maturing porcine oocyte lysates by western blotting ([Figure 3A](#f3-ajas-27-5-635-4){ref-type="fig"}). The level of phospho-p44/42 MAPK increased in 10 μM rapamycin-treated 24 h-aged IVM oocytes compared with untreated 24 h-aged IVM oocytes. The mRNA expression of cytoplasm maturation marker genes (*MOS*, *BMP15*, *GDF9*, and *CCNB1*) was analyzed by real-time RT-PCR ([Figure 3B](#f3-ajas-27-5-635-4){ref-type="fig"}). Although the levels of most genes in untreated 24 h-aged IVM and 10 μM rapamycin-treated 24 h-aged IVM oocytes were lower than those in control IVM oocytes, rapamycin-treated aged IVM oocytes expressed higher levels of *MOS*, *BMP15*, *GDF9*, and *CCNB1* (p\<0.05).

Rapamycin reduces reactive oxygen species activity in aged porcine oocytes *in vitro*
-------------------------------------------------------------------------------------

The effect of rapamycin treatment on ROS activity in oocytes was analyzed. Control IVM (44 h), untreated 24 h-aged IVM (68 h), and 10 μM rapamycin-treated 24 h-aged IVM (44 h+10R/24 h) oocytes were analyzed for ROS activity by the DCHFDA assay in three separate experiments. ROS activity in control IVM (50.00±2.34, [Figure 4A, a; 4B](#f4-ajas-27-5-635-4){ref-type="fig"}) and 10 μM rapamycin-treated 24 h-aged IVM (40.89±1.37, [Figure 4A, c; 4B](#f4-ajas-27-5-635-4){ref-type="fig"}) oocytes was significantly lower than that of untreated aged oocytes (125.89±1.03, p\<0.05, [Figure 4A, b; 4B](#f4-ajas-27-5-635-4){ref-type="fig"}).

To investigate the effect of rapamycin treatment on mitochondrial distribution, blastocysts were stained with Hoechst 33342 to label nuclei and with MitoTracker Green FM to label mitochondria, and analyzed by epifluorescent and confocal microscopy. Blastocysts developed from 10 μM rapamycin-treated aged IVM oocytes (91.33±2.40, p\<0.05, [Figure 4C, g--I; 4D](#f4-ajas-27-5-635-4){ref-type="fig"}) showed a significant increase in green fluorescence compared with those from untreated aged oocytes (64.33±3.48, [Figure 4C, d--f; 4D](#f4-ajas-27-5-635-4){ref-type="fig"}). These values were significantly lower than those from control IVM oocytes (107.00±4.04, p\<0.05, [Figure 4C, a--c; 4D](#f4-ajas-27-5-635-4){ref-type="fig"}).

Rapamycin inhibits mTOR expression in aged porcine oocytes *in vitro*
---------------------------------------------------------------------

The mRNA expression of mTOR in MII oocytes treated with rapamycin was measured by real-time quantitative PCR ([Figure 5](#f5-ajas-27-5-635-4){ref-type="fig"}). It revealed a decrease in mTOR synthesis in 10 μM rapamycin-treated 24 h-aged IVM oocytes ([Figure 5A, g--i](#f5-ajas-27-5-635-4){ref-type="fig"}) compared with control IVM oocytes ([Figure 5A, a--c](#f5-ajas-27-5-635-4){ref-type="fig"}) and untreated 24 h-aged IVM oocytes ([Figure 5A, d--f](#f5-ajas-27-5-635-4){ref-type="fig"}). Specifically, the mRNA expression of *MTOR* complex genes (*MTOR*, *RICTOR*, and *LOC100512677*) was downregulated in 10 μM rapamycin-treated 24 h-aged IVM oocytes compared with untreated 24 h-aged IVM oocytes (p\<0.05, [Figure 5B](#f5-ajas-27-5-635-4){ref-type="fig"}).

To investigate whether the treatment of 10 μM rapamycin in 24 h-aged IVM oocytes could affect the mRNA expression of autophagy-related genes, the expression of *ATG5*, *BECN1*, *ATG7*, *MAP1LC3B*, *ATG12*, *GABARAP*, and *GABARAPL1* was quantified by real-time PCR ([Figure 5C](#f5-ajas-27-5-635-4){ref-type="fig"}). In 10 μM rapamycin-treated 24 h-aged IVM oocytes, there was no difference in *ATG5* expression compared with both control IVM and untreated aged IVM oocytes; however, there was a significant increase in the mRNA expression of other autophagy-related genes such as *BECN1*, *ATG7*, *MAP1LC3B*, *ATG12*, *GABARAP*, and *GABARAPL1* compared with control IVM oocytes (p\<0.05, [Figure 5C](#f5-ajas-27-5-635-4){ref-type="fig"}).

Treatment with rapamycin affects the relative expression of developmentally important genes in blastocysts developed from aged porcine oocytes
----------------------------------------------------------------------------------------------------------------------------------------------

mRNA expression was quantified by real-time PCR ([Figure 6](#f6-ajas-27-5-635-4){ref-type="fig"}). After treatment of 24 h-aged IVM oocytes with 10 μM rapamycin, the mRNA expression of pro-apoptosis genes (*FAS* and *CASP3*) decreased in blastocysts compared with untreated 24 h-aged IVM oocytes; however, the expression of anti-apoptosis genes (*BCL2L1* and *BIRC5*) increased compared with blastocysts developed from control IVM or untreated 24 h-aged IVM oocytes (p\<0.05, [Figure 6](#f6-ajas-27-5-635-4){ref-type="fig"}). Rapamycin treatment in 24 h-aged IVM oocytes did not affect the mRNA expression of the development-related gene, *POU5F1*; however, it did increase the expression of *NANOG* and *SOX2* in blastocysts compared with control IVM and untreated 24 h-aged IVM oocytes (p\<0.05, [Figure 6](#f6-ajas-27-5-635-4){ref-type="fig"}).

DISCUSSION
==========

Until now, our knowledge of anti-aging effectors in oocytes has been limited, and the mechanism of oocyte rescue during aging is unknown. To better understand how rapamycin rescues aged oocytes, the present study investigated the role of this agent in the nuclear and cytoplasmic maturation of oocytes, the production of mitochondrial ROS, and mTOR signaling. Aged IVM oocytes were treated with increasing concentrations of rapamycin (0, 0.1, 1, 10, or 50 μM) for 24 h (68 h; 44 h+R/24 h) or 48 h (92 h; 44 h+R/48 h), respectively. Our results demonstrate that developmental capacity was highest in the 10 μM rapamycin-treated 24 h-aged IVM group, similar to the control IVM group, indicating that rapamycin treatment can rescue the poor developmental capacity of aged porcine oocytes. Furthermore, rapamycin treatment (10 μM) increased total cell number and development-related gene expression, but decreased DNA fragmentation in the 24 h-aged IVM group compared with the untreated 24 h-aged IVM group. Rapamycin-treated aged oocytes showed microtubule rearrangement and an increased phospho-p44/42 MAPK level compared with untreated aged oocytes. There was a significant decrease of ROS activity in rapamycin-treated aged oocytes, and blastocysts showed a normal distribution of mitochondria. During mTOR signaling, *MTOR* mRNA and protein levels were reduced, and autophagy was induced in rapamycin-treated aged oocytes. Moreover, anti-apoptosis processes increased in blastocysts developed from rapamycin-treated aged oocytes, but pro-apoptosis events decreased. The results illustrate that ROS- and mTOR-mediated autophagy affected apoptosis. Therefore, this study shows that rapamycin improves the developmental capacity of blastocysts, and it also reveals that mitochondrial ROS activity and mTOR signaling are involved in oocyte aging.

Instability of centrosomes and microtubules plays a major role in oocyte aging as these ultrastructures are responsible for proper separation of chromosomes at meiotic poles. The adverse effects of suboptimal IVM culture conditions on the structure of the meiotic spindle have been reported in several mammalian species ([@b8-ajas-27-5-635-4]), including the cow, pig ([@b33-ajas-27-5-635-4]), and mouse ([@b30-ajas-27-5-635-4]). These adverse effects appear to be caused by the reduced expression of specific spindle-related genes during aging ([@b25-ajas-27-5-635-4]). In this study, rapamycin treatment increased the frequency of oocytes with normal meiotic spindles compared with untreated aged oocytes. Meiotic spindles in oocytes lack true centrosomes, indicating that specialized mechanisms may be responsible for the off-center positioning of spindles. Furthermore, rapamycin enhanced the rearrangement of abnormal spindles in aged oocytes.

Although we do not yet fully understand the molecular mechanisms in freshly isolated oocytes that are needed to maintain MII spindle dynamics, we know that MAPK and MPF are important. MAPK is a signaling molecule that we have previously shown to associate with centrosome components ([@b35-ajas-27-5-635-4]), and it is thought to be involved in centrosome and microtubule stabilization. Moreover, MAPK activity is gradually reduced during pig oocyte aging ([@b25-ajas-27-5-635-4]; [@b34-ajas-27-5-635-4]). The present study shows that rapamycin-treated aged oocytes exhibit an increase in phosphorylated p44/42 MAPK. Also, there was an increase in the maternal gene expression of *MOS*, *BMP15*, and *GDF9* in rapamycin-treated aged oocytes compared with untreated aged oocytes. Based on these findings, we hypothesize that rapamycin treatment blocked the reduction in maturation by maintaining the ooplasmic status of MII oocytes, and that the enhanced expression of maternal genes may be involved. Collectively, these results indicate that treatment with rapamycin significantly influences MAPK activity and maternal gene expression. Therefore, rapamycin affects the cytoplasmic maturation process in porcine oocytes and improves embryonic developmental competence.

Consequently, *in vitro* blastocyst development and quality was enhanced in rapamycin-treated aged oocytes. The expression of *NANOG* and *SOX2* was also increased in blastocysts developed from rapamycin-treated aged oocytes compared with blastocysts developed from untreated aged oocytes. SOX2 and NANOG interact with POU5F1 to regulate the transcriptional hierarchy that specifies embryonic stem (ES) cell identity ([@b29-ajas-27-5-635-4]; [@b5-ajas-27-5-635-4]; [@b28-ajas-27-5-635-4]). A previous study reported that embryos treated with rapamycin exhibited morphological defects and elevated levels of POU5F1 protein in mouse early embryos ([@b20-ajas-27-5-635-4]). Taken together, rapamycin regulates nuclear and cytoplasmic maturation by rearranging microtubules and rescuing MAPK activity in porcine oocytes *in vitro*. Furthermore, these results indicate that rapamycin is a potent compound that can improve *in vitro* oocyte culture conditions and maintain healthy oocytes.

ROS is a key signaling molecule in several physiological processes such as meiotic resumption. It also plays a role in pathological processes such as cell apoptosis and senescence ([@b1-ajas-27-5-635-4]; [@b38-ajas-27-5-635-4]). In the present study, we demonstrate that rapamycin treatment effectively reduced intracellular ROS levels and increased the surface area of mitochondrial. During embryonic genome activation, mitochondria progressively undergo functional and structural changes, and also generate higher levels of ATP to supply the increasing energy demands of the embryo that result from RNA and protein synthesis and blastocoel formation ([@b18-ajas-27-5-635-4]). Since ROS are generated mainly as by-products of mitochondrial respiration, mitochondria play a fundamental role in aging and represent putative targets of anti-aging strategies ([@b26-ajas-27-5-635-4]). These results illustrate that rapamycin affects mitochondrial function in porcine early embryos developing *in vitro*.

mTOR is an evolutionarily conserved Ser/Thr protein kinase that controls many cellular processes such as cell cycle progression, cell size, transcription, cytoskeleton dynamics, and autophagy in response to a variety of environmental cues ([@b12-ajas-27-5-635-4]; [@b14-ajas-27-5-635-4]; [@b40-ajas-27-5-635-4]). Inhibition of the TOR pathway extends lifespan in yeast, worms, and flies ([@b39-ajas-27-5-635-4]; [@b16-ajas-27-5-635-4]; [@b15-ajas-27-5-635-4]), and a recent study showed that rapamycin, an inhibitor of mTOR, administered late in life extends lifespan in genetically heterogeneous mice ([@b37-ajas-27-5-635-4]; [@b13-ajas-27-5-635-4]). A recent study using loss of function mutational analysis in *C. elegans* showed a clear acceleration in tissue aging and a reduced lifespan in worms with loss of function mutations in the autophagy genes *BEC1, UNC-51*, and *ATG-18* ([@b37-ajas-27-5-635-4]). This shows the importance of autophagy in regulating normal lifespan. In the present study, we showed that rapamycin-treated aged oocytes significantly decreased mTOR protein synthesis and mRNA expression, and that it also affected the expression of the *MTOR* complex gene, *RICTOR*, compared with untreated aged oocytes. Moreover, we observed that autophagy-related gene expression (*MAP1LC3B*, *ATG12*, *GABARAP*, and *GABARAPL1*) increased significantly. These results indicate that rapamycin is involved in the inhibition of mTOR and induced or maintained autophagy via the same signaling pathways to affect oocyte aging. Collectively, these findings suggest that mitochondrial ROS- and mTOR-mediated autophagy may be essential for the regulation of oocyte aging.

Our data show that rapamycin treatment significantly decreased apoptosis in blastocysts developed from rapamycin-treated aged oocytes. Rapamycin also decreased the mRNA levels of both *FAS* and *CASP3*; however, the expression of *BCL2L1* and *BIRC5* increased in blastocysts compared with untreated aged oocytes. *BCL2*, another well-characterized anti-apoptotic gene, can bind *BECN1/ATG6* to inhibit BECN1-mediated autophagy and cell death ([@b24-ajas-27-5-635-4]). A previous study reported that autophagy modulators 3-methyladenine and rapamycin affect the interplay between autophagy and apoptosis in mouse early embryos ([@b20-ajas-27-5-635-4]). These results show that treatment with autophagy modulators increased apoptosis, disrupted mitochondrial morphology, and reduced mitochondrial numbers, as indicated by mtDNA copy number ([@b20-ajas-27-5-635-4]). These results also illustrate that rapamycin plays a role in anti-apoptosis and supports crosstalk between autophagy and apoptosis during porcine early embryo development.

In conclusion, our results show that rapamycin treatment in aged oocytes improved their poor developmental capacity, and that ROS activity and mTOR signaling are involved in porcine oocyte aging. Our results also illustrate that treatment of aged oocytes with rapamycin improved *in vitro* development by rearranging the cytoskeleton and increasing the level of phospho-p44/42 MAPK compared with untreated aged oocytes. Specifically, this study demonstrated that rapamycin increased the quality of blastocysts by affecting the developmental rate and the total cell number, and by decreasing ROS activity, which modulated mitochondrial distribution, apoptosis, autophagy, and mTOR signaling. Thus, rapamycin is a good agent that can be used to prevent the poor developmental competence of porcine oocytes in ART.
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![Effect of rapamycin (R) treatment on the developmental capacity of aged porcine oocytes. (A) Blastocyst morphology in control IVM (44 h; a), untreated 24 h-aged IVM (68 h; b), and 10 μM rapamycin-treated 24 h-aged IVM (44 h+10R/24 h; c) oocytes. (B) Total cell number and (C) DNA fragmentation in control IVM, untreated 24 h-aged IVM, and 10 μM rapamycin-treated 24 h-aged IVM oocytes. Significant differences from control oocytes are indicated (^a--c^ p\<0.05). Values are presented as means±SEM of independent experiments. Bar = 200 μm. IVM, *in vitro* maturation; SEM, standard error of the mean.](ajas-27-5-635-4f1){#f1-ajas-27-5-635-4}

![Effect of rapamycin (R) treatment on the nuclear maturation of aged porcine oocytes. (A) Spindle position in control IVM (44 h; a), untreated 24 h-aged IVM (68 h; b--c), and 10 μM rapamycin-treated 24 h-aged IVM (44 h+10R/24 h; d) oocytes. (B) Percentage of aligned chromosomes and normalspindles in control IVM, untreated 24 h-aged IVM, and 10 μM rapamycin-treated 24 h-aged IVM oocytes. Significant differences from control oocytes are indicated (^a--b^ p\<0.05). Values are presented as means±SEM of independent experiments. α-Tubulin, green; chromatin, red. Bar = 40 μm. IVM, *in vitro* maturation; SEM, standard error of the mean.](ajas-27-5-635-4f2){#f2-ajas-27-5-635-4}

![Effect of rapamycin (R) treatment on the cytoplasmic maturation of aged porcine oocytes. (A) Phosphorylated MAPK activity and (B) maternal gene expression in control IVM (44 h), untreated 24 h-aged IVM (68 h), and 10 μM rapamycin-treated 24 h-aged IVM (44 h+10R/24 h) oocytes. *GAPDH* was used as an internal standard. Significant differences from control oocytes are indicated (^a--b^ p\<0.05). Values are presented as means±SEM of independent experiments. IVM, *in vitro* maturation; SEM, standard error of the mean.](ajas-27-5-635-4f3){#f3-ajas-27-5-635-4}

![Effect of rapamycin (R) treatment on ROS activity and the localization of mitochondria in aged porcine oocytes. (A) ROS activity incontrol IVM (44 h; a, d), untreated 24 h-aged IVM (68 h; b, e), and 10 μM rapamycin-treated 24 h-aged IVM (44 h+10R/24 h; c, f) oocytes. ROS activity was detected with DCHFDA, green. Bar = 200 μm. (B) Quantification of DCHFDA fluorescence intensity in control IVM, untreated 24 h-aged IVM, and 10 μM rapamycin-treated 24 h-aged IVM oocytes. Significant differences from control oocytes are indicated (^a--b^ p\<0.05). (C) The localization of mitochondria in blastocysts derived from control IVM, untreated 24 h-aged IVM, and 10 μM rapamycin-treated 24 h-aged IVM oocytes. Bar = 60 μm. Mitochondria were stained with MitoTracker, green; chromatin, blue. (D) Quantification of MitoTracker fluorescence intensity in control IVM, untreated 24 h-aged IVM, and 10 μM rapamycin-treated 24 h-aged IVM oocytes. Significant differences from control oocytes are indicated (^a--c^ p\<0.05). Values are presented as means±SEM of independent experiments. ROS, reactive oxygen species; IVM, *in vitro* maturation; DCHFDA, dichlorodihydrofluorescein diacetate; SEM, standard error of the mean.](ajas-27-5-635-4f4){#f4-ajas-27-5-635-4}

![Effect of rapamycin (R) treatment on mTOR signaling in aged porcine oocytes. (A) Subcellular localization of mTOR and (B) *MTOR* complex mRNA levels in control IVM (44 h; a--c), untreated 24 h-aged IVM (68 h; d--f), and 10 μM rapamycin-treated 24 h-aged IVM (44 h+10R/24 h; g--i) oocytes. (C) Relative mRNA expression of autophagy-related genes in blastocysts derived from control IVM, untreated 24 h-aged IVM, and 10 μM rapamycin-treated 24 h-aged IVM oocytes. *GAPDH* was used as an internal standard. Significant differences from control oocytes are indicated (^a--c^ p\<0.05). Values are presented as means±SEM of independent experiments. mTOR = green; chromatin = blue. Bar = 40 μm. mTOR, mammalian target of rapamycin; IVM, *in vitro* maturation; SEM, standard error of the mean.](ajas-27-5-635-4f5){#f5-ajas-27-5-635-4}

![Relative mRNA expression of apoptosis- (*BCL2L1*, *BIRC5*, *FAS*, and *CASP3*) and development-(*POU5F1*, *NANOG*, and *SOX2*) related genes in blastocysts derived from control IVM (44 h), untreated 24 h-aged IVM (68 h), and 10 μM rapamycin (R)-treated 24 h-aged IVM (44 h+10R/24 h) oocytes. *GAPDH* was used as an internal standard. Significant differences from control oocytes are indicated (^a--c^ p\<0.05). Values are presented as means±SEM of independent experiments. IVM, *in vitro* maturation; SEM, standard error of the mean.](ajas-27-5-635-4f6){#f6-ajas-27-5-635-4}

###### 

Primers used for real-time PCR

  --------------------------------------------------------------------------------------------------------------
  Gene             GenBank accession no.   Primer sequence            Annealing temp. (EC)   Product size (bp)
  ---------------- ----------------------- -------------------------- ---------------------- -------------------
  *GAPDH*          AF017079                F:GGGCATGAACCATGAGAAGT\    60                     230
                                           R:AAGCAGGGATGATGTTCTGG                            

  *MOS*            NM_001113219            F:TGGGAAGAAACTGGAGGACA\    60                     121
                                           R:TTCGGGTCAGCCCAGGTTCA                            

  *BMP15*          NM_001005155            F:CCCTCGGGTACTACACTATG\    60                     192
                                           R:GGCTGGGCAATCATATCC                              

  *GDF9*           AY_626786               F:GAGCTCAGGACACTCTAAGCT\   60                     272
                                           R:CTTCTCGTGGATGATGTTCTG                           

  *CCNB1*          NM_001170768.1          F:CCAACTGGTTGGTGTCACTG\    60                     195
                                           R:GCTCTCCGAAGAAAATGCAG                            

  *MTOR*           XM_003127584.3          F:AGGAGACCTCCTTTAACCAG\    55                     70
                                           R:ATGTACTTCCTGCACCACTC                            

  *RICTOR*         XM_003483813.1          F:GGTGCTAAAATTGAAAGTGG\    55                     82
                                           R:TGCTTGTGTCCTCTCTACCT                            

  *LOC100512677*   XM_003131151.3          F:GTCACTGCCATGGAGTATCT\    55                     99
                                           R:CAAGTCAGCAAAGTTCTTCC                            

  *ATG5*           NM_001037152.1          F:GAATATGAAGGCACACCACT\    55                     70
                                           R:AAATTGAGGCAAGAAGATCA                            

  *BECN1*          NM_001044530.1          F:TTTTCTGGGACAACAAGTTT\    55                     75
                                           R:CAACCTCTTCTTTGAACTGC                            

  *ATG7*           NM_001190285.1          F:GAACGGGAAGGATTTAATTT\    55                     70
                                           R:CAGTCAAGTCCTCCAAGAAG                            

  *MAP1LC3B*       NM_001190290            F:CCGAACCTTCGAACAGAGAG\    60                     206
                                           R:AGGCTTGGTTAGCATTGAGC                            

  *ATG12*          NM_001190282.1          F:CATCCTACTAAAGGCTGTGG\    55                     92
                                           R:AGTCAATGAGTCCTTGGATG                            

  *GABARAP*        NM_001190288.1          F:CCTCCAGTACTCCTTTCCTT\    55                     78
                                           R:TGACAGAGATGGACAATCAA                            

  *GABARAPL1*      NM_001190287.1          F:TAGGAAACGTTGAGAGGGTA\    55                     76
                                           R:TAACCCCGAAATGAAAATAA                            

  *BCL2L1*         AF216205                F:ACTGAATCAGAAGCGGAAAC\    60                     249
                                           R:AAAGCTCTGATACGCTGTCC                            

  *BIRC5*          NM_214141               F:CCTGGCAGCTCTACCTCAAG\    60                     233
                                           R:GAAAGCACAACCGGATGAAT                            

  *FAS*            AJ001202                F:AAGTTCCCAAGCAAGGGATT\    60                     207
                                           R:AATTTCCCATTGTGGAGCAG                            

  *CASP3*          NM_214131.1             F:GAGGCAGACTTCTTGTATGC\    55                     93
                                           R:ACAAAGTGACTGGATGAACC                            

  *POU5F1*         NM_001113060            F:AGTGAGAGGCAACCTGGAGA\    60                     166
                                           R:TCGTTGCGAATAGTCACTGC                            

  *NANOG*          DQ447201.1              F:GAACTTTCCAACATCCTGAA\    55                     87
                                           R:TTTCTGCCACCTCTTACATT                            

  *SOX2*           EU503117                F:GCCCTGCAGTACAACTCCAT\    60                     216
                                           R:GCTGATCATGTCCCGTAGGT                            
  --------------------------------------------------------------------------------------------------------------

F, forward; R, reverse.

###### 

Effect of rapamycin treatment on the development of aged porcine IVM oocytes

  Treatment group                           Rapamycin conc. (μM)   No. of oocytes                                                Rate[\*](#tfn5-ajas-27-5-635-4){ref-type="table-fn"} (%) of                                                                  
  ----------------------------------------- ---------------------- ------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------
  Control IVM (44 h)                        0                      296                                                           76.00±4.53[c](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}      63.97±3.11[b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}     42.14±4.40[d](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}
  24 h-aged IVM (68 h; 44 h+ wo/w R 24 h)   0                      200                                                           77.67±2.33[c](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}      68.24±9.22[a,b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}   22.04±5.68[b,c](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}
  0.1                                       200                    75.33±7.69[c](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}     68.36±9.76[a,b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}    28.54±2.49[c](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}     
  1                                         200                    75.00±8.74[c](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}     68.32±10.67[a,b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}   28.39±2.76[c](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}     
  10                                        200                    76.67±5.70[c](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}     66.10±0.29[b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}      47.52±5.68[d](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}     
  50                                        207                    77.56±8.25[c](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}     52.01±4.88[a](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}      14.14±3.17[a,b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}   
  48 h-aged IVM (92 h; 44 h+ wo/w R 48 h)   0                      244                                                           60.19±5.66[b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}      45.44±7.51[a](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}     13.50±1.26[a,b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}
  0.1                                       242                    62.55±5.52[b,c](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}   59.01±6.73[a,b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}    9.23±1.92[a](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}      
  1                                         242                    63.45±9.66[b,c](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}   59.78±5.17[a,b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}    5.13±5.13[a](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}      
  10                                        242                    58.49±8.31[a,b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}   68.01±6.04[b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}      10.28±1.33[a,b](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}   
  50                                        242                    44.70±8.42[a](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}     43.97±14.15[a](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}     4.95±2.48[a](#tfn5-ajas-27-5-635-4){ref-type="table-fn"}      

R, rapamycin; IVM, *in vitro* maturation.

Assessed by the presence of a polar body.

Percentages were calculated from cleavage numbers.

p\<0.05.
